HealthcareServices

Chronic Hepatitis B Market Forecast: How Big Will It Be by 2030?

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic hepatitis b market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Chronic Hepatitis B Market expected to reach by 2030?

The chronic hepatitis b market size has experienced consistent growth in recent years. This market is projected to expand from $3.93 billion in 2025 to $4.1 billion in 2026, registering a compound annual growth rate (CAGR) of 4.2%. Historically, this expansion has been driven by elements such as improved hepatitis B screening programs, the wider availability of antiviral drugs, increasing awareness of liver disease complications, an uptick in the use of nucleos(t)ide analogs, and the establishment of long-term disease monitoring protocols.

The chronic hepatitis b market is projected to experience consistent expansion over the upcoming years, with an anticipated growth to $4.74 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.7%. This growth during the forecast period is attributable to several factors, including heightened investments in advanced HBV therapies, a growing demand for treatment regimens with limited durations, the broadened development of therapeutic vaccines, an intensified focus on eradicating viral reservoirs, and enhanced global initiatives for hepatitis elimination. Key trends expected within the forecast timeframe involve the increasing uptake of long-term antiviral treatments, the surging development of functional cure methodologies, a heightened emphasis on prompt disease identification and surveillance, the expansion of strategies for immune-modulating treatments, and improved patient adherence programs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

What Drivers Are Driving Adoption Within The Chronic Hepatitis B Market?

The widespread occurrence of chronic hepatitis B infection is projected to fuel the expansion of the chronic hepatitis B virus market in the coming years. Hepatitis B is a liver ailment caused by the hepatitis B virus (HBV), which is preventable via vaccination. The escalating rates of hepatitis B infection are attributable to various factors, particularly in low- and middle-income countries, where insufficient vaccination coverage leads to heightened transmission rates as a significant portion of the population remains unprotected. These increasing hepatitis B infection rates are expected to boost the demand for diagnostic tests and treatment alternatives. For instance, in June 2024, a report published by the Centers for Disease Control and Prevention (CDC), a US-based government agency, stated that elevating global hepatitis B vaccination coverage to 90% and treatment access to 80% could avert 26 million new infections and 9 million deaths attributable to hepatitis B between 2022 and 2050. In 2022, there were 1.2 million new cases of hepatitis B virus (HBV) infection. Consequently, the high prevalence of hepatitis B infection will notably drive the chronic hepatitis B virus market.

What Segments Are Included Within The Chronic Hepatitis B Market?

The chronic hepatitis b market covered in this report is segmented –

1) By Drug Class: Antivirals, Immune Modulators

2) By Gender: Male, Female

3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Antivirals: Nucleos(T) Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon)

2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)

How Are Emerging Trends Affecting The Progression Of The Chronic Hepatitis B Market?

Leading firms within the chronic hepatitis B market are concentrating on technological innovations, including novel antiviral treatments. These novel antiviral therapies represent cutting-edge drugs designed to combat viral infections, particularly those that are resistant, by preventing viral replication and employing sophisticated delivery methods. Their safety and effectiveness are currently being evaluated in clinical trials, with bepirovirsen serving as an example for chronic hepatitis B. As an illustration, in February 2024, GSK plc, a multinational pharmaceutical and biotechnology company based in the UK that focuses on the research, development, production, and marketing of diverse healthcare offerings, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for bepirovirsen. This investigational antisense oligonucleotide (ASO) is intended for the treatment of chronic hepatitis B (CHB). Bepirovirsen’s mechanism involves targeting and breaking down the RNA of the hepatitis B virus (HBV), which could enable the body’s immune system to reassert control against the infection. This medication has shown encouraging outcomes in its Phase IIb trials, particularly in the B-Clear and B-Sure studies, proving effective at lowering hepatitis B surface antigen (HBsAg) levels and maintaining viral suppression over time.

Who Are The Prominent Global Companies Shaping The Chronic Hepatitis B Market Landscape?

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Which Region Currently Holds The Largest Share Of The Chronic Hepatitis B Market?

North America was the largest region in the chronic hepatitis B market in 2025. The regions covered in the chronic hepatitis b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Hepatitis B Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp

Browse Through More Reports Similar to the Global Chronic Hepatitis B Market 2026, By The Business Research Company

Viral Hepatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Hepatitis B Virus Hbv Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795